Crescent and Kelun-Biotech swap cancer asset rights in double deal

Crescent Biopharma and Kelun-Biotech have entered a strategic partnership to exchange rights to their cancer drugs, with Crescent paying $80m upfront and up to $1.25bn in milestones for Kelun's ADC, and Kelun paying $20m and $30m in milestones for Crescent's bispecific antibody. Both deals include royalties on future sales. This partnership is part of a growing trend of collaborations between Western and Chinese biopharma companies.

Crescent Biopharma and Kelun-Biotech Launch Strategic Oncology Partnership

Crescent Biopharma Inc. and Kelun-Biotech have formed a strategic partnership to develop and commercialize novel oncology therapeutics. Crescent granted Kelun-Biotech exclusive rights to CR-001 in Greater China, while Crescent received exclusive rights to SKB105 outside Greater China. Both drug candidates are expected to enter Phase 1/2 clinical trials in early 2026. The collaboration aims to accelerate development and maximize the potential of these cancer treatments globally.

Crescent Biopharma’s Strategic Growth and Competitive Edge Justify Buy Rating

Stifel Nicolaus analyst Stephen Willey maintains a Buy rating on Crescent Biopharma (CBIO) due to strategic growth and competitive positioning. The company's agreement with Sichuan Kelun-Biotech enhances its pipeline with a promising ADC, and its ambitious CR-001 monotherapy development strategy targets solid tumors. LifeSci Capital also maintains a Buy rating with a $22.00 price target, highlighting Crescent's potential for clinical differentiation and competitive edge.

Crescent Biopharma shares are trading higher after the company announced a partnership with Sichuan Kelun-Biotech Biopharmaceutical. The company secured a $185 million private placement.

Why Is Crescent Biopharma Stock (CBIO) Up Today?

Why Is Crescent Biopharma Stock (CBIO) Up Today?